Download PDF

Summary

  • Physician scientist with 15 yrs. of experience in basic, translational and clinical research, with a focus on cardiovascular disease, advanced imaging and implementation of advanced technology in healthcare.
  • Successfully collaborated across institutions and disciplines with experts in biological, clinical and engineering sciences.
  • Authored and co-authored peer reviewed publications and national and international conference proceedings in basic, translational and clinical research.
  • Currently advising medtech startups and innovation centers on clinical strategies, non-traditional funding strategies and industry relations.

Work experience

AMGEN, Inc.

2022Present

Global Clinical Development, Clinical Research Medical Director, Clinical Omics

  • Partner for Therapeutic Area leads within Clinical Development and Biomarkers for multi-omic strategies for better understanding the disease state, patient population and potential use of a omics in our clinical trials.
  • Clinical partner for discovery and preclinical asset/disease state teams.
  • Working with in-house and external partners for dataset acquisition and/or analysis of existing datasets to further understand disease states of interest.
  • External collaborations with academic and industry partners on aligned interests in multi-omic datasets to better understand disease and diseased patient populations.
  • Diversification of our patient population cohorts to understand diseases of interest  across: gender, geography, socio-economics, race and ethnicity. 

AMGEN, Inc.

20192022

Global Clinical Development, Cardiometabolic Sr. Medical Scientist

  • Clinical study lead for evolocumab (Repatha) Open Label Extension studies 20130295 and 20160250, 2021-Present.
    • Medical guidance for GCTM, RCTM and Biostats, study document review
    • L3 study reviews with MDRs
    • Planning, generation and review of Tables Figures and Listing Shells
    • Medical support for Eastern Europe, Western Europe and USA.
  • Next Generation Trial Execution "Tiger Team Lead" supporting high priority projects
    • Providing data-centric solutions to clinical study teams internally to:
      • Speed up startup and execution
      • Shorten overall study duration
      • Lowering overall study cost
      • Potentially bringing treatments to market earlier
  • Medical Monitor for omecamtiv mecarbil, GALACTIC-HF, 2019-2020.
    • Medical support for 440 sites in Latin America, Russia, Ukraine and Eastern Europe.
    • Worked with colleagues in operations on database cleaning, site queries for safety and primary endpoints in addition to working on lost to follow-up subjects and in preparation for end of study for Latina America, Eastern Europe, Russia and Ukraine.
    • Worked with cross-functional colleagues in preparation for database lock, final analysis and regulatory filing.

AMGEN Inc.

20162019

Sr. Regional Medical Liaison

  • Co-leadership on a cross-functional collaborative effort that led to:
    • Identification of ~1.5 Million patients through the analysis of real world data that would further benefit from disease state awareness, education of guideline therapies and further medical treatment.
    • Presented the Medical Liaison strategy to identify, engage and educate KOLs, HCPs, Societies and IDNs in relation to the identified disease state.
    • Worked collaboratively with a cross-functional team to present an executive summary to US Medical leadership.
  • Proposal to the US Medical Team and RML Sr. Leadership that identified and emphasized the importance of a disease state that currently affects approximately on the CV population that could further benefit from disease state awareness and guideline education.
    • Invited to an “in-house” rotation at headquarters with Cardiometabolic US Medical Team (~3.5 mths) and designated by US Medical Lead to Co-lead a workstream while maintaining robust territory support in the field.
  • Worked with commercial and Health Outcomes and Pharmacoeconomic colleagues in a compliant fashion to improve access to care for cardiovascular patients.
  • Established working relationships with leading physicians and researchers in the Texas Medical Center in Heart Failure and Atherosclerotic disease.
    • Developed a relationship with HFSA leadership, with whom an established field relationship existed.
  • Expanded healthcare practitioner portfolio for Heart Failure and Atherosclerosis.
  • Worked with opinion leaders at the local, regional and national level in scientific engagement, educational activities, AMGEN research opportunities and Investigator Initiated Studies.
  • Worked with internal and external stakeholders at regional and national conferences to provide value to healthcare providers and patients.
  • Worked together with Clinical Research Associates, Clinical Trial Organization Managers, Study Leads to provide input on future study sites, to provide feedback from current study sites and to troubleshoot issues that are communicated from PI’s.

WeaRobot. Houston, TX, USA.

20162017

Chief Medical Officer

  • Established working relationships with leading physicians in the Texas Medical Center.
  • Physically and legally establishing WeaRobot in the U.S.A..
  • Actively looking for non-dilutive and dilutive funding opportunities in the United States.
  • Coordinating a working relationship with a pioneer in Virtual Reality for implementation of our technology in mixed reality environments.

Department of Surgery, Baylor College of Medicine. Houston, Texas, USA.

20142016

Research Associate

Mentor: Steve A. Curley, MD

  • Established a working relationship with a biomaterials engineering group to complement the material science and engineering expertise with basic, translational and clinical science experience at Baylor College of Medicine.
  • Established a working relationship with the Emerging Analytics Center at UALR to coordinate an effort to bring Virtual Reality and Augmented Reality to Baylor College of Medicine as a teaching tool for students, residents and clinicians in virtual, augmented and mixed-reality environments.
  • Effect of RF on the tumor Immune-microenvironment:
    • Developed a hypothesis with Jared M. Newton based on preliminary results.
    • Developed the protocol design with Jared M. Newton.
    • Analyzed flow cytometry data with Jared M. Newton.
  • Designed an imaging protocol for non-invasive biomarkers for the diagnosis, prognosis and evaluation of chronic liver pathologies in humans, expanded into a "Pilot Grant" to better characterize liver masses non-invasively.
  • Established working relationships with academia and industry to better understand the tumor microenvironment through novel and advanced in-vivo and ex-vivo imaging techniques, with the ultimate goal of understanding the tissue and vascular characteristics of malignant masses.
  • Participated extensively in grantsmanship with members of the collaborative effort using in-vivo and ex-vivo novel imaging techniques to better understand the tumor microenvironment.

Atherosclerosis and Vascular Biology Training Center, Department of Internal Medicine, Baylor College of Medicine. Houston, Texas, USA.

20132014

T32 Postdoctoral Fellowship

Mentors: Gerd Brunner, PhD and Dipan J. Shah, MD.

  • Continued the retrospective clinical study in Atrial Fibrillation under a T32 training grant at Baylor College of Medicine under the supervision of Gerd Brunner, PhD and Dipan J. Shah, MD.
  • Executed tracing of left atrial contours, quantification of hyperenhancement within the left atrial wall, gathering of clinically significant findings and statistical analysis of preliminary data.
    • Wrote a manuscript of clinical and imaging parameters that may predict Afib recurrence (Pending).
    • Wrote a funded "Pilot Grant" with data obtained from the retrospective study for a prospective study.
  • Measured effective orifice area of bioprosthetic aortic valves through CMR in a comparison study with ECHO and performed statistical analysis of results (Publication 1).

Department of Cardiology, Cardiovascular MRI, The Methodist DeBakey Cardiology Heart & Vascular Center. Houston, Texas, USA

20132013

Postdoctoral Fellowship

Mentors: Dipan J. Shah, MD and Gerd Brunner, PhD.

  • Lead a retrospective clinical study proposed to delineate the relationship between functional cardiac parameters and recurrence in patients treated for Afib with Atrial Fibrillation Catheter Ablation (AFCA) through Cardiovascular Magnetic Resonance (CMR) under the supervision of Gerd Brunner, PhD and Dipan J. Shah, MD.
  • Measured and analyzed changes in Left Atrial Scar and Function between baseline and follow-up in a cohort of patients that are undergoing AFCA or AFCA+ETOH in an ongoing clinical trial at Houston Methodist Hospital (PI: Dr. Miguel Valderrabano).

Department of Cardiology, Heart Failure and Cardiac Transplantation, The Methodist DeBakey Cardiology Heart & Vascular Center. Houston, Texas, USA

20102013

Postdoctoral Fellowship

Mentor: Guillermo Torre-Amione, MD, PhD.

  • Designed and executed projects involving cardiomyocyte isolation and nanoparticle uptake  in collaboration with Ulises Ruiz-Esparza; during this time various cardiovascular cell lines were tested for nanoparticle uptake (Publication 2).
  • Acquired, interpreted and analyzed ECHO and MR imaging in heart failure animal models (Publications 3 and 5).
  • Designed, executed and participated in basic science studies and retrospective clinical research in heart failure and the role that the immune system plays in the disease models (Publications 3, 9 and 12).

Basic Sciences Department, Escuela de Medicina Ignacio A. Santos, Instituto Tecnologico de Monterrey.

20022003

Research Assistant

Mentor: Jorge E. Moreno, MD, PhD.

  • Learned: sterile technique, in-vitro experimental setup, protocol implementation and tissue culture.

Education

Escuela de Medicina Ignacio A. Santos, Instituto Tecnologico de Monterrey.

20002010

Combined Undergraduate and Doctor of Medicine (M.D.)

Community Clinica "La Fama", Escuela de Medicina Ignacio A. Santos, Instituto Tecnologico de Monterrey.

20092010

General Practitioner, Social Service

Sta. Catarina, N.L., Mexico.

Department of Cardiology, Heart Failure and Cardiac Transplantation. The Methodist DeBakey Heart & Vascular Center. Houston, Texas, USA

20082009

Predoctoral Fellowship

Mentor: Guillermo Torre-Amione, MD, PhD.

  • Designed and implemented a protocol for the use of a natural extract from Phaseolus vulgaris L. (Publication 5) to ameliorate fibrosis in cardiac heart failure.
  • Learned: RNA extraction, PCR, Primary Tissue Culture, Scientific Presentation, Protocol Design and Execution, Gel Electrophoresis, Scientific Writing (Publication 13), Ethical Treatment of Animals, Animal Models of Heart Failure, Minor and Major Animal Surgeries, In-Vivo Experimental Design and execution.

University of Miami/Jackson Memorial Medical Center, Lilian Jean Kaplan Renal Transplantation Center.

20052005

Surgical Research Internship and Clinical Observership.

Skills

* Creativity and Innovation * Leadership * Professionalism *  Organization * Critical Thinking * Communication * Networking * New Business Development * Strategic Planning * Cardiac MRI * Clinical Research * Translational Research * Protocol Design * Grantsmanship * Fluent Spanish and English *

Peer Review and Other Professional Activities

  • 2016-Present     Member, Editorial Board for mHealth Journal
  • 2014-2019          Advisory Council Expert for Next Wave Connect
  • 2013-Present     Member, Society for Cardiovascular Magnetic Resonance
  • 2011-2014          Journal Reviewer for Health and Technology, Elsevier.

Advisory Roles:

  • 2015-Aug. 2016:   WeaRobot a modular exoskeleton for motion assistance, rehabilitation and human augmentation.
  • 2016-Present:      Lazarus 3D, a 3D printing company that allows for prototyping tissue like organs for surgical  education and/or planning.

Research and Support

Past:

  • Federally funded by NIH grant #T32HL07812, Atherosclerosis and Vascular Biology Training Center (#HL07812-03), Department of Internal Medicine, Section of Atherosclerosis at Baylor College of Medicine. PI: Christie M. Ballantyne, MD

Publications and Conference Proceedings

Peer Reviewed Publications in Press:

  1. O'Donoghue ML, Giugliano RP, Wiviott SD, Atar D, Keech A, Kuder JF, Im K, Murpy SA, Flores-Arredondo JH, Lopez JAG, Elliott-Davey M, Wang B, Monsalvo ML, Abbasi S., Sabatine MS. Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease. Circulation. 2022 Oct 11. doi/10.1161/CIRCULATIONAHA.122.061620
  2. Levintow SN, Orroth KK, Breskin A, Park AS, Flores-Arredondo JH, Dluzniewski P, Navar AM, Sorensen HT, Brookhart MA. Use of Negative Control Outcomes to Assess the Comparability of Patients Initiating Lipid-lowering Therapies. Pharmacoepidemiol Drug Safety. 2021 Dec 11. doi: 10.1002/pds.5396
  3. Teerlink JR, et al. Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF. J Am Coll Cardiol. 2021 Jul 13;78(2):97-108. doi: 10.1016/j.jacc.2021.04.065
  4. Maragiannis D, Jackson MS, Autry K, Flores-Arredondo JH, Aggeli C, Tousoulis D, Zoghbi WA, Shah DJ, Little SH. Functional assessment of biosprosthetic mitral valves by cardiovascular magnetic resonance: An in vitro validation and comparison to Doppler echocardiography. J Cardiovasc Magn Reson. 2020 Jul 30;22(1):55. doi: 10.1186/s12968-020-00635-x
  5. Maragianis D, Jackson MS, Flores-Arredondo JH, Autry K, Schutt RC, Alvarez PA, Zoghbi WA, Shah DJ, Little SH. Effective Orifice Area by Phase Contrast CMR. JACC Imaging.  May, 2016. DOI: 10.1016/j.jcmg.2015.08.025
  6. Ruiz-Esparza GU, Segura-Ibarra V, Cordero-Reyes A, Youker KA, Serda RE, Cruz-Solbes AS, Amione-Guerra J, Yokoi K, Kirui DK, Cara FE, Paez-Mayorga J, Flores-Arredondo JH, Guerrero-Beltran CE, Garcia-Rivas G, Ferrari M, Blanco E, Torre-Amione G. A specifically designed nanoconstruct associates, internalizes, traffics in cardiovascular cells and accumulates in failing myocardium: A new platform for heart failure diagnostics and therapeutics. European Journal of Heart Failure. February 2016. DOI: 10.1002/ejhf.463
  7. Cordero-Reyes AM, Youker KA, Trevino AR, Celis R, Hamilton DJ, Flores-Arredondo JH, Orrego CM, Bhimaraj A, Estep JD, Torre-Amione G. Full Expression of Cardiomyopathy Is Partly Dependent on B‐Cells: A Pathway That Involves Cytokine Activation, Immunoglobulin Deposition, and Activation of Apoptosis. J Am Heart Assoc. 2016 Jan 14;5(1). PMID: 26769625
  8. Flores-Arredondo JH and Assad-Kottner C. Virtual Reality: A look into the past to fuel the future.  The Bulletin of the Royal College of Surgeons of England 2015 97:10, 424-426. DOI: 10.1308/rcsbull.2015.424
  9. Garcia-Rivas G, Youker KA, Orrego C, Flores-Arredondo JH, Guerrero-Beltran CE, Cordero-Reyes AM, Gutierrez-Uribe JA, Gutierrez M, Serna-Saldivar SO, Torre-Amione G. Standardized extract from black bean coat (Phaseolus vulgaris L.) prevents adverse cardiac remodeling in a murine model of non-ischemic cardiomyopathy.  RSC Advances. October 2015. DOI:10.1039/C5RA07715J
  10. Chaikriangkrai K, Lopez-Mattei J, Flores-Arredondo JH, Chang SM, Reardon M, Shah DJ. Adult-form Scimitar Syndrome. Case Report. Methodist DeBakey Heart and Vascular Journal. Oct-Dec, 2014. PMID: 25624983.
  11. Saul Campos-Gomez, Jose H Flores-Arredondo, Rita Dorantes-Heredia, Mónica Chapa-Ibargüengoitia, Roberto De la Peña-López. Case Report: Anti-hormonal Therapy in the Treatment of Ductal Carcinoma of the Parotid Gland. BMC Cancer. 2014 Sep 23; 14(1);701. PMID: 25249211
  12. Campos-Gomez S, Valero V, Flores-Arredondo JH, Isassi-Chapa A, Rangel-Rodríguez I, Hortobagyi GN,  Gonzalez-Angulo AM. Breast cancer subtype and baseline characteristics from diabetic breast cancer patients are not different from non-diabetics. Breast J. 2014 May 26. PMID: 24862358
  13. Youker KA, Assad-Kottner C, Cordero-Reyes AM, Trevino AR, Flores-Arredondo JH, Barrios R, Fernandez-Sada E, Estep JD, Bhimaraj A, Torre-Amione G. High proportion of patients with end-stage heart failure regardless of aetiology demonstrates anti-cardiac antibody deposition in failing myocardium: humoral activation, a potential contributor of disease progression. European Heart Journal. Published online December 29, 2013. PMID: 24375073
  14. Rodarte-Shade M, Torres-Barrera G, Flores-Arredondo JH, Rumbaut-Diaz R. Hybrid Technique for Removal of Eroded Adjustable Gastric Band.  Journal of the Society of Laparoendoscopic Surgeons.  2013 Apr-Jun;17(2):338-41. PMID: 23925033
  15. Ruiz Esparza GU, Flores-Arredondo JH, Segura-Ibarra V, Torre-Amione G, Ferrari M, Blanco E, Serda RE. The physiology of cardiovascular disease and innovative liposomal platforms for therapy. International Journal of Nanotechnology.  Volume 2013:8, 629-640. February 2013. PMID: 23413209
  16. Orrego CM, Nasir N, Oliveira GH, Flores-Arredondo JH, Cordero-Reyes AM, Loebe M, Youker KA, Torre-Amione G.  Cellular Evidence Of Reverse Cardiac Remodeling Induced by Cardiac Resynchronization Therapy (CRT).  Congest Heart Fail. May-Jun;17(3):140-6.  May 2011. PMID: 21609388
  17. Flores-Arredondo JH, García-Rivas G, Torre-Amione G.  Immune Modulation in Heart Failure:  Past Challenges and Future Hopes.  Current Heart Failure Reports. Volume 8, Number 1, 28-37.  January 2011. PMID: 21221862

Conference Proceedings:

Local and Regional:

  1. Flores-Arredondo JH. DCE-MRI for evaluating the efficacy of non-invasive radiofrequency cancer hyperthermia.  3rd Annual Small Animal Imaging Facility Symposium. Texas Children’s Hospital. 10 minute presentation. May 12th, 2016.
  2. S. Suki, Y. Mackeyev, N. Lara, M. Pulikkathara, C. Mark, N. Kumar, M. Cheney, JH Flores-Arredondo, L. Vergara, L. Wilson, S. Curley, R. Serda. Contribution of Carbon and Silica Nanoparticles to Heating and Cell Death in a Non-invasive Radiofrequency Field.  Cancer Prevention Research Institute of Texas. Austin, November 2015.
  3. Flores-Arredondo JH. The Influence of Radiofrequency Energy on Tumor Immunology. Small Animal Imaging Facility Symposium. Texas Children’s Hospital. 10 minute presentation. May 21st, 2015.

National and International:

  1. Effective Orifice Area by Cardiac Magnetic Resonance for the Functional Assessment of Bioprosthetic Aortic Valves. Maragiannis D, Little SH, Jackson MS, Flores-Arredondo JH, Alvarez P, Shah DJ, Zoghbi WA. Poster accepted for presentation in San Diego at ACC 2015.
  2. Detection of Left Atrial Scar and Changes of Cardiac Function in Relation to AF Ablation, by 3D Late Gadolinium Enhancement. Flores-Arredondo JH, Brunner G, Abboud L, Morrisett JD, Ballantyne CM, Dave AS,  Zoghbi WA, Valderrabano M, Shah DJ. Abstract accepted for SCMR 2014.
  3. Adult-form Scimitar Syndrome. Chaikriangkrai K, Lopez-Mattei J, Flores-Arredondo JH, Chang SM, Reardon M, Shah DJ. Case Report accepted for SCMR 2014.
  4. Cellular Association of Nanocarriers in Cardiac Cells.  Ruiz-Esparza GU, Blanco E, Shamdueen S, Flores-Arredondo JH, Serda R, Ferrari M, Torre-Amione G. Poster presentation in San Francisco.  Poster accepted for ACC 2013
  5. The Histological Importance of Signet Ring Cell and Mucinous Adenocarcinoma on Outcomes in Patients with Colorectal Cancer.  S Campos-Gomez, V Rosa-Camargo, RA Ramirez-Fallas, JH Flores-Arredondo, L Morales-Juarez, SI Perez-Alvarez, D Valdez-Bocanegra, D Huitzil-Melendez.  Annals of Oncology. 37th ESMO Congress.  Vol. 23, Supplement 9.  September 2012.
  6. Full Expression of Acute Non-Ischemic Cardiomyopathy in a Murine Model is Dependent on Intact B Cell Function.  AM Cordero-Reyes, KA Youker, JH Flores-Arredondo, AR. Trevino, C Assad-Kottner, JD Estep, A Bhimaraj, G Torre-Amione.  Journal of Cardiac Failure. Vol. 18 Issue 8 Pg S2. August 2012.
  7. Proposed Echocardiographic Algorithm To Predict Elevated Left Ventricular Filling Pressures in Patients Supported with Continuous-Flow Left Ventricular Assist Devices. Estep, J.D.; Vivo, R.P.; Flores-Arredondo, J.H.; Krim, S.R.; Aldeiri, M.; Elias, B.; Kurchock, B.; Loebe, M.; Bruckner, B.; Torre-Amione, G.; Bhimaraj, A.  Mini Oral Presentation at ISHLT 32nd Annual Meeting and Scientific Sessions.  April 2012.
  8. Deposito de CU2+ Intra-miocardico en Falla Cardiaca: Objetivo Terapeutico Potencial Para Terapia?  Flores-Arredondo, Jose H., Assad-Kottner, Christian, Youker, Keith A.,  Orrego, Carlos M., Torre-Amione, Guillermo.  Congreso Anual de Cardiología Internacional (CADECI).  Guadalajara, México. February 2012.
  9. Depósitos de anticuerpos anti-cardíacos en pacientes con insuficiencia cardíaca y su posible contribución en el desarrollo y progresión de la enfermedad. Christian Assad-Kottner, Andrea M. Cordero-Reyes, Alejandro R. Trevino, Jose H Flores-Arredondo, Evaristo Fernandez, Roberto Barrios, Keith A Youker,  Guillermo Torre-Amione.  Mini Oral Presentation at Congreso Anual de Cardiología Internacional (CADECI).  Guadalajara, México. February 2012.
  10. Cardiac fibrosis induced by Angiotensin II is dependent on a radiation sensitive or bone marrow derived cell. Jose H. Flores-Arredondo, Andrea Cordero-Reyes, Alejandro Trevino, Keith A. Youker, Jerry D. Estep, Carlos M. Orrego and Guillermo Torre-Amione. Journal of Cardiac Failure Vol. 17, Issue 8, Supplement, Page S35. August 2011.
  11. Evidence of Anti-Cardiac Antibody Deposition in End-Stage Failing Myocardium: A Potential Contributor to Disease Progression. Alejandro Trevino, Jose H. Flores-Arredondo, Roberto Barrios, Keith A. Youker, Andrea M. Cordero-Reyes, Jerry D. Estep, Carlos M. Orrego, Guillermo Torre-Amione. Journal of Cardiac Failure Vol. 17, Issue 8, Supplement, Page S35.  August 2011.
  12. Intact T and B Cell Responses Are Required for Full Expression of Acute Non-Ischemic Cardiomyopathy. Andrea Cordero-Reyes, Keith A. Youker, Jose H. Flores-Arredondo, Alejandro Trevino, Jerry D. Estep, Carlos M. Orrego, Guillermo Torre-Amione.   Mini Oral Presentation at Heart Failure Society of America, 2011.  Journal of Cardiac Failure Vol. 17, Issue 8, Supplement, Page S2.  August 2011.
  13. Cardiac Resynchronization Therapy (CRT) Induced Cellular Reverse Cardiac Remodeling Similar to Left Ventricular Assist Devices.  C.M. Orrego, Jose H. Flores-Arredondo, K. Youker, G. Torre-Amione. The Journal of Heart and Lung Transplantation Vol. 29, Issue 2, Supplement, Page S72. February 2010
  14. Protective Effect of BBTMH-007 on Development of Cardiomyopathy.  Keith A. Youker, Ahmad Khalil, Jose H. Flores-Arredondo, Sergio Serna, Jorge Moreno, Jerry D. Estep, Guillermo Torre-Amione.  Poster presentation in Atlanta.  J. Am. Coll. Cardiol. 2010;55;A19.E182.
  15. Black Bean Extract Inhibits Cardiac Fibrosis and Restores Cardiac Function in an Acute Non-Ischemic Cardiomyopathy Mouse Model.  Keith A. Youker, Ahmad Khalil, Carlos Orrego, Jose H Flores-Arredondo, Sergio Serrano, Jorge Moreno, Guillermo Torre-Amione; Heart Failure Society of America.  Poster Presentation September 14, 2009.